A patented, DSMZ-deposited spore-former with genomic characterization, clinical investigation and the capability for industrial-scale surfactin production.
Bacillus subtilis MM40® (DSM 21097; Budapest Treaty DSM 33619; EU Trademark No. 018279328) is a fully genomically characterized bacterial strain, deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ) and protected by a granted EU patent.
| Organism | Bacillus subtilis - gram-positive, rod-shaped, aerobic, motile |
| Classification | Spore-former (endospore-forming bacterium) |
| Deposited at | DSMZ - German Collection of Microorganisms and Cell Cultures |
| Designation | MM40® (DSM 33619, derived from DSM 21097) |
| Identity Confirmed by | CeGaT laboratory analysis (whole genome sequencing) |
| Patent Protection | EU Patent EP3964195 (granted) |
| Spore Formation | Resistant endospores - survives gastric acid, heat, ambient storage |
| Shelf Stability | Up to 2 years at room temperature |
| Key Capability | Surfactin production (cyclic lipopeptide biosurfactant) |
The limitations of conventional probiotics have initiated a fundamental shift in research. Spore-forming organisms like Bacillus subtilis represent a promising approach.
Conventional strains such as Lactobacillus and Bifidobacterium lose up to 99% of their viability during gastric transit in studies. They require refrigeration, are sensitive to heat and moisture, and have limited shelf life.
B. subtilis MM40® produces resistant endospores that survive gastric acid, heat and ambient storage. The strain germinates in the intestine and is metabolically active there. No refrigeration required - shelf-stable up to 2 years.
Survives temperatures that inactivate conventional strains
Natural protection against gastric acid through spore coat
No refrigeration needed - up to 2 years at room temperature
Germinates in the intestinal tract and deploys metabolic activity
Surfactin is a cyclic lipopeptide with surface-active properties, described in the scientific literature as one of the most potent natural biosurfactants.
MM40® is capable of producing surfactin at industrial scale. The substance is the subject of extensive scientific research across multiple application fields.
Disclaimer: The properties of surfactin described herein refer to the scientific literature. These are not approved health claims.
A factual comparison with other commercially available Bacillus subtilis strains based on documented characteristics.
| Characteristic | MM40® Magnat Vital |
CU1 Gnosis / Lesaffre |
DE111 ADM (Deerland) |
HU58 Viridis BioPharma |
|---|---|---|---|---|
| Clinical RCT (placebo-controlled, human subjects) | ✓ | ✓ | ✓ | ✓ |
| In vitro antimicrobial data | ✓ | ✗ | ✓ | ✓ |
| Granted EU patent | ✓ | ✗ | ✗ | ✗ |
| Surfactin production documented | ✓ | ✗ | ✗ | ✗ |
| DSMZ deposit | ✓ | ✗ | ✗ | ✗ |
Disclaimer: This comparison is based on publicly available information and publications. It does not claim to be exhaustive. Unmarked entries indicate that no corresponding public data was available at the time of compilation - not necessarily that the characteristic is absent.
Discover the scientific evidence behind MM40® or speak directly with our team about partnership opportunities.
